Goodell V - Search Results

1

Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.

Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA. Disis ML, et al. Among authors: goodell v. J Clin Oncol. 2004 May 15;22(10):1916-25. doi: 10.1200/JCO.2004.09.005. J Clin Oncol. 2004. PMID: 15143085 Clinical Trial.

2

Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients.

Disis ML, Goodell V, Schiffman K, Knutson KL. Disis ML, et al. Among authors: goodell v. J Clin Immunol. 2004 Sep;24(5):571-8. doi: 10.1023/B:JOCI.0000040928.67495.52. J Clin Immunol. 2004. PMID: 15359116 Clinical Trial.

3

Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase.

Montgomery RB, Makary E, Schiffman K, Goodell V, Disis ML. Montgomery RB, et al. Among authors: goodell v. Cancer Res. 2005 Jan 15;65(2):650-6. Cancer Res. 2005. PMID: 15695410

4

Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity.

Goodell V, Disis ML. Goodell V, et al. J Immunol Methods. 2005 Apr;299(1-2):129-38. doi: 10.1016/j.jim.2005.02.002. Epub 2005 Mar 18. J Immunol Methods. 2005. PMID: 15914197

5

Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.

Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML. Goodell V, et al. J Clin Oncol. 2006 Feb 10;24(5):762-8. doi: 10.1200/JCO.2005.03.2813. Epub 2006 Jan 3. J Clin Oncol. 2006. PMID: 16391298

6

Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.

Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML. Dang Y, et al. Among authors: goodell v. Clin Cancer Res. 2007 Mar 15;13(6):1883-91. doi: 10.1158/1078-0432.CCR-06-2083. Clin Cancer Res. 2007. PMID: 17363545

7

Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers.

Salazar LG, Coveler AL, Swensen RE, Gooley TA, Goodell V, Schiffman K, Disis ML. Salazar LG, et al. Among authors: goodell v. Clin Immunol. 2007 Dec;125(3):275-80. doi: 10.1016/j.clim.2007.08.006. Epub 2007 Oct 29. Clin Immunol. 2007. PMID: 17913588 Clinical Trial.

8

Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity.

Coveler AL, Goodell V, Webster DJ, Salazar LG, Fintak PA, Childs JS, Higgins DM, Disis ML. Coveler AL, et al. Among authors: goodell v. Breast Cancer Res Treat. 2009 Jan;113(1):95-100. doi: 10.1007/s10549-008-9910-y. Epub 2008 Jan 31. Breast Cancer Res Treat. 2009. PMID: 18236151

9

Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity.

Goodell V, Waisman J, Salazar LG, de la Rosa C, Link J, Coveler AL, Childs JS, Fintak PA, Higgins DM, Disis ML. Goodell V, et al. Mol Cancer Ther. 2008 Mar;7(3):449-54. doi: 10.1158/1535-7163.MCT-07-0386. Epub 2008 Mar 4. Mol Cancer Ther. 2008. PMID: 18319334

10

Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer.

Lu H, Goodell V, Disis ML. Lu H, et al. Among authors: goodell v. Expert Opin Ther Targets. 2007 Feb;11(2):235-44. doi: 10.1517/14728222.11.2.235. Expert Opin Ther Targets. 2007. PMID: 17227237 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters